Loading...
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?
Bronte, G Silvestris, N Castiglia, M Galvano, A Passiglia, F Sortino, G Cicero, G Rolfo, C Peeters, M Bazan, V
Bronte, G
Silvestris, N
Castiglia, M
Galvano, A
Passiglia, F
Sortino, G
Cicero, G
Rolfo, C
Peeters, M
Bazan, V
Citations
Altmetric:
Genre
Journal Article
Date
2015-01-01
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.18632/oncotarget.4959
Abstract
Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.
Description
Citation
Citation to related work
Impact Journals, LLC
Has part
Oncotarget
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu